EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Socioeconomic Deprivation Associated with Worse Survival in Patients with Cancer Included... March 23, 2021 Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... October 13, 2025 ΗΛΕΚΤΡΟΧΗΜΕΙΟΘΕΡΑΠΕΙΑ: Η ΝΕΑ ΠΡΩΤΟΠΟΡΙΑΚΗ ΠΡΟΣΕΓΓΙΣΗ ΓΙΑ ΘΕΡΑΠΕΙΑ ΟΓΚΩΝ September 10, 2019 Boy Asks Mom Fighting Cancer To Take Off Her Turban So... May 4, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ Dad With Cancer Escorts His Autistic Son To School, With The... Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung...
